AbbVie’s Elagolix Wins FDA Priority Review to Manage Endometriosis with Associated Pain
News
The U.S. Food and Drug Administration (FDA) has granted priority review to AbbVie’s investigational medicine, Elagolix — formerly known as ABT-620 — for managing endometriosis with associated pain. Elagolix is an oral gonadotropin-releasing ... Read more
